IDEANOMICS, INC.: Nasdaq/NYSE listing notice — Ideanomics receives Nasdaq deficiency notice for audit committee composition after director resignation

IDEANOMICS, INC.

Jerry Fan resigned from board and audit committee on April 29, 2023, leaving audit committee with only 2 independent directors, below the required minimum of three.
Nasdaq granted a cure period until earlier of next annual meeting or May 31, 2024; if annual meeting before Nov 27, 2023, compliance required by Nov 27, 2023.
Company plans to appoint an additional independent director promptly but cannot assure regaining compliance; failure could lead to delisting of IDEX.
The letter has no immediate effect on trading; stock continues listed on Nasdaq under symbol IDEX.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

IDEANOMICS, INC. received a nasdaq deficiency notice notice regarding audit committee (rules 5605).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: audit committee
Rules: 5605

Exact text from the filing

June 2, 2023, Ideanomics, Inc. (the “Company”) received a letter (the “Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was no longer in compliance with the independent director and audit committee requirements as set forth in Nasdaq Listing Rule 5605, which requires the Audit Committee of the Board of Directors of the Company (the “Audit Committee”) to be comprised of a minimum of three independent directors. As previously reported, on April 29, 2023, the board accepted and received the resignation of Mr. Jerry Fan from the Company’s board and audit committee

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-23-070224

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.